Strengthening the anticancer drug and ASEAN businesses through a capital and business alliance with Lotus Pharmaceutical
First written in FY2019-Q2. 1 of 3 entries say "Restated". Latest entry: FY2022.
No other company in this theme has enough history to compare yet.
- FY2022AdvancedAnnual report
「We have filed marketing applications for 2 products containing 1 active ingredient of an anti-hematological malignancy drug jointly developed with Lotus Pharmaceutical Co., Ltd.」
The filing of marketing applications for 2 products containing 1 active ingredient of an anti-hematological malignancy drug is cited as a specific development relating to the jointly developed products under the capital and business alliance with Lotus Pharmaceutical. - FY2019-Q3RestatedAnnual report
「In addition, on 20 March 2019, we entered into an agreement on a capital and business alliance with Lotus Pharmaceutical Co., Ltd., a listed Taiwanese company in the same Alvogen Group, to strengthen our anticancer drug business in Japan and achieve mutual complementarity in manufacturing and sales in Asia, particularly in ASEAN. Through these alliances, we will not only further enhance the value of our business in Japan, but also expand opportunities to operate globally.」
The stated objectives of the capital and business alliance with Lotus Pharmaceutical, namely strengthening the anticancer drug business, achieving mutual complementarity in Asia, particularly in ASEAN, and expanding opportunities for global business development, continue to be disclosed. - FY2019-Q2First statedAnnual report
「In addition, on 20 March 2019, we entered into an agreement on a capital and business alliance with Lotus Pharmaceutical Co., Ltd., a listed Taiwanese company in the same Alvogen Group, to strengthen our anticancer drug business in Japan and achieve mutual complementarity in manufacturing and sales in Asia, particularly in ASEAN. Through these alliances, we will not only further enhance the value of our business in Japan, but also expand opportunities to operate globally.」
An agreement on a capital and business alliance with Lotus Pharmaceutical was signed on 20 March 2019. The alliance is intended to strengthen the anticancer drug business in Japan, achieve mutual complementarity in manufacturing and sales in Asia, particularly in ASEAN, and expand opportunities for global business development.